In April 2022, HOPA submitted a proposal to the Board of Pharmacy Specialties to continue to provide professional development programs for the recertification of board-certified pharmacists. With BPS's approval, HOPA is proud to provide Board Certified Oncology Pharmacy (BCOP) continuing education for another seven years. The new contract begins January 1, 2024 and runs through December 31, 2030.

Read the announcement: BPS Announces Professional Development Programs Approved for the Recertification of Board-Certified Pharmacists beginning in January 2024

HOPA Provides at Least 60 BCOP CEs Each Year

Each year, HOPA provides at least 60 BCOP Continuing Education Credits for members and other board certified hematology/oncology pharmacists. Explore the latest BCOP Updates and BCOP Self-Study Releases and more!

Tools and Resources Late Breaking News

Related Articles

Read all latest news Right Pointing Arrow
Breast cancer image
Tools and Resources Drug Updates

Pharmacist's Application to Practice: Sacituzumab govitecan-hziy

December 12, 2024

Brooke Kielkowski, PharmD, PGY2 Oncology Pharmacy Resident, and Jordan Hill, PharmD, BCOP, Pharmacy Clinical Specialist, both from WVU Medicine - West Virginia University Hospitals, Morgantown, WV, write about sacituzumab govitecan-hziy (Trodelvy).

stomach cancer image
Tools and Resources Drug Updates

Pharmacist's Application to Practice: Zolbetuximab-clzb

December 12, 2024

Olivia Tholt, PharmD, PGY2 Oncology Pharmacy Resident, and Sarah Cimino, PharmD, BCOP, Clinical Pharmacist Specialist, Gastrointestinal Oncology, both from Vanderbilt University Medical Center, Nashville, TN, write about zolbetuximab-clzb (Vyloy).

Tools and Resources Drug Updates

Pharmacist's Application to Practice: Vorasidenib

November 20, 2024

Lacy La Fever, PharmD, MS, PGY2 Oncology Pharmacy Resident, and Anastasia Graham, PharmD, MBA, BCOP, Clinical Oncology Specialist, Neuro-oncology, both from Medical University of South Carolina, Charleston, SC, write about vorasidenib (Voranigo).